FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.

This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in patients with moderately to severely active Crohn’s disease. In this expert-led discussion, she summarizes findings from the GALAXI 2 and GALAXI 3 clinical trials presented at a 2026 medical congress, which used a treat-through study design intended to reflect real-world clinical practice. The focus of the analysis is on how patients with Crohn’s disease respond over time when treated with guselkumab compared to placebo.

The data presented focuses on key outcomes such as improvement and resolution of extraintestinal manifestations, including joint and skin symptoms, along with measures like steroid-free remission and the emergence of new symptoms over time. At baseline, a notable proportion of patients in both the guselkumab and placebo groups had extraintestinal involvement, most commonly arthralgia, with skin manifestations occurring less frequently.

This educational FAQ highlights how clinicians are evaluating guselkumab as part of a broader strategy for managing Crohn’s disease, with attention to both symptom control and durability of response over time. It provides practical insights for gastroenterology advanced practice providers and healthcare professionals as they balance effectiveness, long-term disease control, and comprehensive care of patients with inflammatory bowel disease in clinical practice. Visit the GHAPP Website, GHAPP Digital Hub or GHAPP ACE app for additional educational content.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(164)

Linerixibat Medication Review

Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in p...

22 Sep 13min

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact o...

15 Sep 15min

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liv...

25 Aug 20min

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Jul 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Jun 17min